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ABSTRACT: A theory for deriving drug-DNA site binding constants from footprinting data is presented. 
Plots of oligonucleotide concentration, as a function of drug concentration, for various cutting positions on 
D N A  are required. I t  is assumed that the rate of cleavage at  each nucleotide position is proportional to 
the concentration of enzyme at  that nucleotide and to the probability that the nucleotide is not blocked by 
drug. The probability of a nucleotide position not being blocked is calculated by assuming a conventional 
binding equilibrium for each binding site with exclusions for overlapping sites. The theory has been used 
to evaluate individual site binding constants for the antiviral agent netropsin toward a 139 base pair restriction 
fragment of pBR-322 DNA. Drug binding constants, evaluated from footprinting data in the presence of 
calf thymus D N A  and poly(dGdC) as carrier and in the absence of carrier DNA, were determined by 
obtaining the best fit between calculated and experimental footprinting data. Although the strong sites 
on the fragment were all of the type (T-A),, the value of the binding constant was strongly sequence dependent. 
Sites containing the dinucleotide sequence 5'-TA-3' were found to have significantly lower binding constants 
than those without this sequence, suggesting that an adenine-adenine clash produces a D N A  structural 
alteration in the minor groove which discourages netropsin binding to DNA. The errors, scope, and limitations 
associated with the method are presented and discussed. 
Footprinting analysis is widely used in studying ligand 
binding to DNA. The approach, which utilizes DNA se- 
quencing technology, relies on the ability of a DNA-bound 
ligand to inhibit DNA cleavage at its binding site. Since the 
initial footprinting studies involving the lac repressor-DNA 
interaction (Galas & Schmitz, 1978; Schmitz & Galas 1979), 
the method has been used to study a variety of DNA binding 
proteins (Johnson et al., 1979; Sakonju & Brown, 1982) as 
well as drugs (Dabrowiak, 1983; Lane et al., 1983; Low et al., 
1984; Scamrov & Beabealashvilli, 1983; Van Dyke et al., 1982; 
Dervan, 1986) which are capable of binding to DNA in a 
sequence-specific manner. The DNA-hydrolyzing enzymes 
DNase I and DNase I1 (Drew, 1984), a variety of metal 
complexes (Dervan, 1986; Tulluis & Dombroski, 1986; Ku- 
wabara et al., 1986; Ward et al., 1987), alkylating agents 
(Ogata & Gilbert, 1979; Ward & Dabrowiak, 1987), and UV 
radiation (Becker & Wang, 1984) have been used as probes 
to identify ligand binding sites in the footprinting experiment. 
Aside from simply revealing the sites of ligand binding, 
footprinting analysis has the potential for yielding thermo- 
dynamic information on ligand-DNA binding as a function 
of sequence. Unlike any other method, it allows evaluation 
of individual site binding isotherms and thus provides direct 
information on ligand binding constants as a function of the 
sequence of DNA bases. Although the bulk of the footprinting 
experiments reported to date has been qualitative in nature 
and has focused on identifying the interaction sites of DNA 
binding ligands, recent elegant work of Ackers and co-workers 
(Brenowitz et al., 1986a,b; Senear et al., 1986) demonstrated 
that footprinting data can be used to measure thermodynamic 
quantities associated with the binding of bacteriophage X CI 
repressor to right and left operators. 
Although the extension of quantitative footprinting analysis 
to small ligand-DNA studies appears straightforward, certain 
characteristics of these ligands complicate the extraction of 
thermodynamic data. Binding constants of drugs are in most 
cases several orders of magnitude less than those of DNA 
binding proteins. Thus, the DNA cleaving agents or probes 
that are used to score ligand sites may in fact disturb the 
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ligand-DNA interaction that is being measured. A second 
important factor associated with drugs concerns their small 
size and relatively low binding sequence specificities. Since 
they have low specificities, they bind to many sites on DNA, 
thereby displacing the probe from DNA. If either the lig- 
and-DNA or the probe-DNA equilibrium were disturbed 
during the experiment, the concentrations of oligonucleotides 
produced in the footprinting digests would not reflect the true 
binding isotherms for the various site loading events taking 
place in the system. Finally, it has been shown (Ward et al., 
1987, 1988) that binding of drugs to DNA causes an increase 
in DNase I cleavage away from the site of binding. This 
enhancement, explained by redistribution of the enzyme on 
DNA as binding sites load with drug, needs to be taken into 
account in determining binding constants from footprinting 
data. 
Using the antiviral agent netropsin and a 139-base segment 
+ 
n2Y\ 
/ 
c-NHCH~CONH 
N e t r o p s i r  
of pBR-322 DNA, we earlier demonstrated that it is possible 
to uncover the individual site loading events on the restriction 
fragment with two probes, the enzyme DNase I and a cleaving 
cationic manganese porphyrin complex (Ward et al., 1987). 
Footprinting plots, showing the rate of cleavage of the probe 
as a function of netropsin concentration and sequence, revealed 
the sites of strong and weak drug binding and regions of 
enhancement on the fragment. In this paper we present the 
first quantitative analysis of DNase I footprinting titrations 
involving netropsin and show how values may be derived for 
site-specific drug binding constants on a DNA restriction 
fragment. The method does not require an independent de- 
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termination of the free drug concentration during the foot- 
printing titration. This quantity, along with the individual site 
isotherms and the binding constants, is determined by a 
minimization approach involving only the measured foot- 
printing autoradiographic spot intensities and the total drug 
concentration. In addition to defining the scope and limitations 
of the method, we present new evidence that netropsin can 
discriminate between high-affinity sites of the type (A-T), in 
a sequence-dependent fashion. 
MATERIALS AND METHODS 
The various footprinting studies involving netropsin and the 
139 base pair restriction fragment of pBR-322 DNA and data 
analysis using linear scanning microdensitometry were as 
earlier described (Ward et al., 1987, 1988; Dabrowiak et al., 
1986). Briefly, the total DNA concentration in base pairs for 
the experiments involving poly(dGdC) and calf thymus DNA 
as carrier was -194 pM (-1 pM fragment and 193 pM 
carrier) in a buffer consisting of 50 mM tris(hydroxy- 
methy1)aminomethane hydrochloride (Tris-HCl), 8 mM 
MgC12, and 2 mM CaCl, at pH 7.5. The experiments in- 
volving only the labeled fragment (no carrier) were carried 
out at -1 pM base pairs. All digests, at 37 OC, were ter- 
minated early such that -80% of the 139-mer remained un- 
cleaved during the various reactions. The concentration of 
DNase I in the experiment involving poly(dGdC) and calf 
thymus DNA as carrier was -2 X lo-’ M while the enzyme 
concentration for the no-carrier experiment was -2 X lo-* 
M. 
Each footprinting titration yielded a series of footprinting 
plots showing oligonucleotide concentration, as a function of 
drug concentration, for 61 sites on the 139-mer. The auto- 
radiographic data were scanned with a linear scanning mi- 
crodensitometer computer system yielding cross-sectional areas 
directly proportioned to oligonucleotide concentration (Da- 
browiak et al., 1986). The oligonucleotide concentrations 
(areas) ai were corrected for differences in the total extent of 
digest for a given reaction. These corrections were usually 
<lo% (Ward et al., 1987). The present analysis, aimed at 
identifying the binding constants for strong sites of netrop- 
sin-DNA interaction, considered only the early loading events 
on the 139-mer, so only the lower drug concentrations were 
used. Sequence analysis revealed all the strong sites to be of 
the type (A-T),. 
Densitometric scanning of the autoradiographic data (Da- 
browiak et al., 1986) also showed that the total amount of 
cleavage on the restriction fragment for all experiments was 
constant over the concentration range during which the strong 
sites on the fragment were accepting drug. This observation 
eliminated the need for correcting the observed footprinting 
plots for a shift in the enzymeDNA equilibrium as drug was 
added to the system. 
The sequence of the fragment studied along with the loca- 
tions of strong netropsin binding is shown in Figure l .  Se- 
lected densitometric scans of autoradiographic data are given 
in Figure 2. In order to determine individual site binding 
constants when overlapping drug sites were involved, it was 
necessary to monitor the site loading events at as many points 
as possible throughout the overlap region. The observed 
footprinting plots and the calculated plots for the most highly 
overlapped region of the fragment, having the sequence 5’- 
CAGTTAAATT-3’, positions 53-62, are shown in Figures 3 
and 4. 
In the case of calf thymus DNA as carrier, the sites at 45, 
48, 50, 54, 55, 59, 62, 63, 85, 87, 90, and 154 were used to 
monitor strong binding to the fragment while those at 53, 71, 
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5’-4GCTTT44lGCGGT4GTlTblC4CbGll444~lGCTb4CGC4GTC4GGC4CCGlGT4lG444lCl4AC4A 
3 ’ ”  *AAATT4CGCC4lC444lAGTGTC44lTT4bCG4llGCGTC4GTCCGTGGC4C4l4CTll4GAlTGl~ 
4 0  50 60 70 E O  90 - 
TGCGCTCblCGTCPlCCTCGGCbCCGTCIiCCClGGAlGCTGlAGGC4~4GGCl~GGllAlG~CGG~4CTGCt - 3
bCGCG4GT4GCAGl4GG4GCCGTGGCbGlGGG4CCl4CG4C~TCCGl4TCCG44CC44T4CGGCC4lGACGGC-5 
100 110 I20 130 140 :50 160 170 - 
FIGURE 1: Sequence of the 139 base pair, HindIIIINciI restriction 
fragment of pBR-322 DNA. The locations of netropsin binding are 
indicated with a solid rectangle (four nucleotides long) on the sequence. 
The fragment is end labeled (32P) a t  position 33. 
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FIGURE 2: Densitometric scans of selected autoradiographic data 
involving netropsin and the 139-mer in the presence of calf thymus 
D N A  (193 pM base pairs). DNase I alone (-); 7.8 WM netropsin 
(-), the strong sites; 39 pM netropsin (--), the strong and weak sites. 
114, and 102 measured the enhancement effect due to re- 
distribution of enzyme on DNA (Ward et al., 1988). Sixteen 
netropsin concentrations C in the range 0 I C I 8.99 X 10“ 
M were used in this analysis. There were thus 256 intensities 
(oligonucleotide concentrations) to be fitted. 
For the experiments using poly(dGdC) as carrier, the sites 
used for strong drug binding were 49, 50, 54, 55, 56, 57, 58, 
59, 60, 62, 87, 154, and 90; data for sites 102 and 114 were 
used to monitor the enhancement. The number of sites, along 
with six drug concentrations, in the range 0 I C I 4.97 X lo-’ 
M, gave rise to 90 concentrations to be fitted. 
For the carrier-free experiments, the sites monitored were 
48, 49, 50, 53, 54, 55, 57, 58, 59, 62, 71, 85, 87, 90, 92, and 
98. All showed the effect of drug binding to strong sites except 
53, 71, and 98, which monitored enhancement. Since there 
were 11 drug concentrations, in the range 0 I C I 1.95 X IO-’ 
M, 176 intensities (oligonucleotide concentrations) were used 
in the determination of equilibrium constants. Due to a small 
amount of background cleavage observed in the control lanes 
of the gel, a “background” densitometric scan was subtracted 
from all scans in the carrier-free experiments. 
THEORY 
The rate of cleavage by DNase I at an exposed phospho- 
diester linkage of DNA, (rate)i, is governed by expression 1, 
(rate), = k:[DNase IIi (1) 
where k:  is the cleavage rate constant at the site and [DNase 
IIi is the concentration of enzyme at the site. A site on DNA 
becomes inaccessible to the enzyme when a drug molecule 
binds in such a way as to block the hydrolysis of the phos- 
phodiester linkage. Assuming that (rate)i is then reduced to 
0, we write, instead of ( l ) ,  eq 2, where pi is the probability 
(rate), = k:[DNase I]gi (2) 
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FIGURE 3: Observed (0) and calculated (0) oligonucleotide areas 
(concentrations) as a function of the logarithm of the total netropsin 
concentration, log C, for the no carrier experiment. The quantity, 
x ,  a correction factor for slight differences in the extent of digest, 
and a,, the linearly scaned band area, were determined as earlier 
described (Ward et al., 1987; Dabrowiak et al., 1986). 
that site i is not blocked to the enzyme by bound drug. As 
evidence that drug binding totally blocks cleavage, we note 
that, for some sites such as 59 and 90, the cleavage rate can 
be reduced essentially to 0 by addition of drug. 
Since the footprinting digests are terminated early enough 
so that one is in the "single-hit" regime, the concentrations 
of the various oligonucleotides produced by cleavage are 
proportional to the initial cutting rates at the corresponding 
sites. Thus, the observed oligonucleotide concentrations reflect 
the equilibrium drug binding situation over the sites which 
exists before cleavage of DNA takes place (Goodisman & 
Dabrowiak, 1985). To predict these concentrations for com- 
parison to experiment, one has to calculate the lpi\ as a function 
of total drug concentration. In order to do so, other factors 
that affect the rate must be considered. 
0 . 7 5  1 
G'15* 0 . 0  -10.0 - 5 . 2  - 8 . 4  - 7 . 6  - 6 . 8  -6 
log c 
FIGURE 4: Observed (0) and calculated (0) oligonucleotide areas 
(concentrations) as a function of the logarithm of the total netropsin 
concentration, log C, for the no-carrier experiment. Quantities x and 
ai are defined as in Figure 3. 
If, for example, drug binding to one site produces a struc- 
tural change in DNA within a binding region of another drug 
site, i.e., a change in ki, the measured spot intensities associated 
with the second site will not reflect the true occupancy of the 
site. Although this is not likely to occur for netropsin, which 
is known to cause little distortion to DNA (Kopka et al., 1985), 
other effects are known to exist. 
Correction of Redistribution of DNase I on DNA. The 
amount of cleavage at a particular site can be affected by 
changes in [DNase IIi as drug loading on the restriction 
fragment takes place. Previous studies with netropsin and the 
139-mer revealed that the total amount of cleavage on the 
fragment remains constant while the strong sites are accepting 
drug (Ward et al., 1987, 1988). This shows that the amount 
of enzyme on the fragment is constant and that drug binding 
simply shifts enzyme to other sites on the fragment. Since drug 
binding at one site on a restriction fragment increases [DNase 
IIi at  other unoccupied sites on the same fragment, the spot 
intensities associated with these sites must be corrected for 
this enhancement. Since fractional enhancements at almost 
all nonbinding sites were observed to be essentially the same, 
we take the enhancement effect into account by writing 
(3) [DNase IIi = (1 + ab)[DNase IliO 
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where a is a constant to be determined and b is the amount 
of bound drug on a fragment. The enhancement factor of 1 
+ ab applies to binding as well as nonbinding sites. 
If it is true that the enhancement arises because drug at one 
site shifts enzyme to other sites, without decreasing the amount 
of enzyme on the fragment, the factor 1 + ab should be re- 
placed by ( 1  - ab)-’. This would correspond to an even dis- 
tribution of enzyme over all sites as would occur with a fa- 
cilitated diffusion mechanism (Winter & von Hipple, 198 1 ) .  
As long as ab is not large compared to unity, ( 1  - ab)-’ is 
essentially the same as 1 + ab. In fact, we have found that 
replacing the latter by the former gives rise to only extremely 
small changes in the results of our calculations. 
The effective concentration of DNase I at a particular site 
i in the absence of drug, [DNase IIn, may be incorporated into 
the effective rate constant. Since the concentration of a 
particular oligonucleotide produced in the footprinting digest 
ci is proportional to the initial cleavage rate constant and the 
measured area ai is proportional to the oligonucleotide con- 
centration, we have 
ai = kgi ( l  + ab) ( 4 )  
where ki = k:[DNase IliO multiplied by the digest time. 
Site Exclusion. The value of pi obviously depends on the 
drug binding equilibrium constant for site i ,  Ki, on the drug 
concentration, and on the total concentration of restriction 
fragment present in the system. Consideration of the structure 
of DNase I and the length of netropsin on DNA suggested 
that drug binding to site i actually blocks seven or eight sites 
from DNase I cleavage (Suck & Oefner, 1986; Ward et al., 
1988). Four sites are blocked due to the length of netropsin 
on DNA, while three or four additional sites are blocked due 
to the relative orientation between a loop on the enzyme and 
its cleavage site. In the following analysis of netropsin foot- 
printing data, it will be evident that the exact size of the 
protection region, seven or eight nucleotides, may also depend 
on the specific sequence of DNA at which binding is taking 
place. However, for the purpose of discussing site exclusion 
a protection region of seven is assumed, implying that seven 
nucleotide positions can be used to measure Ki. Alternatively, 
pi depends on all of the values of Kj, with j between i - 3 and 
i + 3. By “binding of a drug at  site j”, we mean netropsin 
occupation of nucleotide positions j ,  j + 1 ,  j + 2, and j + 3. 
For an isolated site i ,  the binding equilibrium is 
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centration of any base pair j ) ,  so be the concentration of 
binding regions of the type (A-T), with no drug bound, and 
sj be the concentration of binding regions of the type (A-T), 
with drug bound at  site j within the binding region. Then 
where Do is the free drug concentration and v b  is the fraction 
of site bound by drug, vb = 1 - pi .  However, the situation is 
complicated by the existence of overlapping binding sites. For 
example, (A-T), is composed of two overlapping netropsin sites 
which are each four nucleotides long. One involves base pairs 
from i to i + 3 while the other involves base pairs i + 1 to i 
+ 4. Base pairs i + 1 to i + 3 are occluded by binding to either 
site. On a given DNA restriction fragment only one of these 
situations can occur, so that binding to one tetrameric sequence 
excludes binding at the other overlapping tetrameric sequence 
on the same fragment. 
Although McGee and von Hippel (1974) and Epstein (1978) 
have presented a treatment of such exclusion for a lattice of 
identical binding sites, not all overlapping sites have the same 
binding constant on the restriction fragment studied. In the 
case of netropsin, the exclusion obtains for binding regions of 
the type (A-T),, where n = 5-7. To treat these, let Kj be the 
binding constant for a particular nucleotide position j ,  s be 
the fragment concentration (which is also equal to the con- 
and 
since the exclusion means that only a totally empty binding 
region can bind drug. The probability of having drug bound 
at  site j is s j / s .  From eq 6 and 7 one can show 
where the sum is over all the binding sites: two for a 5-mer, 
three for a 6-mer, and four for a 7-mer. 
Now consider cutting at  a base pair i which can be blocked 
by drugs bound at  different tetramers of a binding region. If 
drug at any of the 4-mers of the binding region blocks cutting 
at i ,  the fraction of that base pair which is free, 1 - vb, is given 
by 1 - Cj(s j /s ) .  However, if only drug binding at sites p and 
q, say, stops cutting (because of the position of site i relative 
to the binding region) 
so that, in the numerator, we have 1 + DoC’Kj, with C ’ K j  
being over all base pairs in the binding region for which drug 
binding does not affect cutting. 
Determination of the Free Drug Concentration. All the 
expressions involve the free drug concentration rather than the 
total drug concentration, and it is only the latter that is known 
in the footprinting experiment. For an experiment with no 
carrier, or an experiment with a carrier that does not bind drug, 
the free drug concentration Do is obtained from the total drug 
concentration D, by subtracting the concentration of drug 
bound to the restriction fragment. If we consider all sites 
where drug may bind (including sites for which drug binding 
is monitored directly via the footprinting) 
D, = Do + b 
and 
b = C S ~  = SDoCKi/(l + KiDo) (10)  
i i 
assuming all sites are isolated sites. Therefore, Do can be 
obtained by solving 
Ki 
D, = Do + sDoC 
i 1 + KiDo 
For a binding region for which exclusion is a factor, D&/( 1 
If a carrier that binds drug (e.g., calf thymus DNA) is 
present in large excess, the free drug concentration Do is largely 
determined by the carrier. Let c be the carrier site concen- 
tration in base pairs. Supposing all the carrier sites to have 
the same binding constant K,, we have D, = Do + cx and 
(12) 
where x is the fraction of carrier site bound by drug. Since 
the amount of drug bound to fragment is small compared to 
the amount bound to carrier and since c is only an effective 
+ KiDo) is replaced by DO(CkKk)/(l + CkKkDO). 
CX/DO(C - CX) = K,  
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Table I:  Equilibrium Binding Constants for Netropsin as a Function 
of Sequence (XIOd M)“ 
carrier DNA 
calf 
nucleotide Poly- thymus 
Dosition seauence of site (dGdC’, none DNA 
~~ 
46 5’-TTTA-3’ 1.9 7.0 5.5 
47 5’-TTAT-3’ 10 68 87 
56 5’-TTAA-3’ 4.2 1.8 3.4 
57 5‘-TAAA-3’ 6 39 14.5 
AAAT 
AATA 
AATT 
ATTT 
TTTA 
TTAA 
58 5’-AAAT-3’ 35 164 167 
59 5’- AATT-3’ 35 70 131 
89 5’-AAAT-3’ 34 100 145 
156 5‘-TTAT-3‘ 3.6 12 82 
TTTA 
AATA 
“The position of the lowest numbered nucleotide of a tetramer 
binding site is given. 
site concentration, exclusions for sites of the type (AmT),, when 
n = 5-7, need not be considered. Although one could consider 
several kinds of sites on the carrier, with different binding 
constants, it does not seem necessary with our present data. 
The preceding discussion shows how spot intensities for 
various sites can be calculated for a given total drug concen- 
tration, given values for the constants k, (one for each nu- 
cleotide where binding or enhancement are measured), Ki (one 
for each four-nucleotide site where drug binding occurs), a, 
and K,  (if carrier, rather than the fragment, controls the free 
drug concentration). We determine these constants by seeking 
the values for which calculated and experimental intensities 
differ as little as possible. This is done by minimizing the sum 
of squared deviations as follows. Assuming a set of Ki, we solve 
eq 11 or 12 to obtain Do and b corresponding to each given 
D,. Then ub is calculated for each nucleotide and each con- 
centration. The optimum values of the ki are found by min- 
imizing the mean-square deviation between the experimental 
and calculated (eq 4) spot intensities for each base pair, as- 
suming a value for a. We then search, using the Fletcher- 
Davidon-Powell simplex method (Fletcher, 1980), for the set 
of Ki and a (and K,  if necessary) which makes the sum of the 
squared deviations of theoretical from experimental spot in- 
tensities as small as possible. 
RESULTS 
From the fitting procedure, the cleavage rate constants at 
various nucleotide positions, the drug equilibrium constants, 
and a redistribution constant associated with DNase I were 
obtained for each experiment. In the tables given in the 
supplementary material (see paragraph at  end of paper re- 
garding supplementary material), calculated and experimental 
intensities are compared point by point. The equilibrium 
constants are given in Table I. Some calculated plots are 
compared with experimental plots in Figures 3 and 4. The 
difference in plots as one goes from site to site through a 
binding region, and the way in which the theoretical curves 
reproduce the experimental, should be noted. 
Table I shows that while the binding constants for the ex- 
periments involving no carrier DNA and calf thymus DNA 
as carrier are in good agreement with each other, the values 
Table 11: Effect of Change in Base Pair Concentration on Derived 
Equilibrium Constants (XlO-’ M)“ 
fragment concn 
constant 1.5 X lod M 1 X lod M 6.67 X lo-’ M 
K46 0.6 0.7 0.7 
K41 8.2 6.8 5.9 
KS6 0.2 0.2 0.2 
K51 4.1 3.9 3.1 
KS8 19.6 16.4 14.5 
KS, 1.7 7.0 6.1 
K09 13.5 10.0 8.2 
K1S6 1.4 1.2 1.1 
“The data used are from the experiment involving no carrier DNA. 
obtained in the presence of poly(dGdC) are significantly lower 
than those obtained in the former cases. However, the relative 
binding constants agree for the three experiments, thus al- 
lowing establishment of the order of the affinities of the various 
sites. The order found, in decreasing values of K ,  was (all 5’ 
4 3’) AAAT (58, 89) > AATT (59) - TTAT (47, 156) > 
TAAA (57) > (46) - TTAA (56). Since site 156 appeared 
in a poorly resolved region of the autoradiogram and the 
intensity of only one band was used to monitor the loading 
event, Figure 2, the value of K for this site is less certain than 
the remaining values in Table I. 
To determine how the concentration of the fragment would 
affect the values of K for the various sites, a series of mini- 
mization calculations in which the value of the fragment 
concentration was varied was carried out. The results of these 
determinations for the experiment involving no carrier DNA 
are given in Table 11. As is evident from the table, significant 
changes in the concentration of the fragment have only a 
modest effect on the value of K .  
DISCUSSION 
Netropsin-DNA Binding Constants. The data in Table I 
reveal striking new information about the sequence dependence 
of the netropsin-DNA interaction. Consideration of the se- 
quences of the sites with the lowest binding constants, TAAA 
(46, 57), TTAT (47), and TTAA (56) revealed that they 
contain the dinucleotide sequence TA. As has been previously 
outlined by Calladine (1982), this sequence gives rise to a 
strong clash in the minor groove between adenine bases on 
opposite polynucleotide strands. This clash may be relieved 
by a number of mechanisms, ultimately giving rise to a local 
distortion in DNA away from the idealized B form of the helix. 
Since netropsin utilizes specific hydrogen bonds and van der 
Waals contacts with the floor of the minor groove (Kopka et 
al., 1985), the distortions produced by the TA step very likely 
reduce optimal drug-DNA contact and with it the binding 
constant. The tetrameric sequences having the highest binding 
constants of about -lo8 M-l, AAAT ( 5 8 ,  89) and AATT 
( 5 9 ) ,  do not possess the sequence TA. These sites would be 
expected to more closely conform to the B-helical structure 
adopted by the AT core sequence in the duplex d- 
(CGCGAATTCGCG)2 (Wing et al., 1980) and present op- 
timal hydrogen bonding and van der Waals contacts toward 
netropsin. Although variable-temperature footprinting studies 
will be necessary to determine the contributions made by AH 
and A S  to the free energy of binding, recent studies suggest 
that AS for the netropsin-DNA interaction may be relatively 
sequence independent (Marky & Breslauer, 1987). In this 
case, enthalpic effects, which have their origins in the different 
structural features of the tetrameric binding sequences, would 
appear to be the controlling factor in the netropsin-DNA 
interaction. 
Q U A N T I T A T I V E  F O O T P R I N T I N G  S T U D I E S  
The effect that flanking bases may have on the binding 
constant of netropsin is difficult to discern from the data 
presented in Table 1. For example, the sequence TAAA which 
occurs at positions 46 and 57 possesses different flanking bases 
in the two locations of the fragment. Ascertaining whether 
or not these differences in the netropsin binding constants are 
real, and if or to what extent flanking bases can influence 
netropsin binding to a core sequence, will require additional 
quantitative footprinting studies. 
Although comparison of the binding constants in Table I 
with values determined by other methods is not possible in most 
cases, netropsin binding to the sequence AATT has recently 
been studied by calorimetry (Marky & Breslauer, 1987). This 
sequence, when present in the duplex d(GCGAATTCGC)2, 
was found to bind netropsin with a binding constant of 2.84 
X los  M-l, with [Na+] = 16 mM, and d log K/d log [Na+] 
of -1.55. The main cationic components in the footprinting 
experiments are 10 mM Ca2+ plus Mgz+. Taking this as 
equivalent to 40 mM Na+, we estimate K for our conditions 
as 6.9 X lo7 M-', which is in good agreement with the values 
given in Table I for the sequence AATT. 
The values in Table I do not in general agree with the order 
of binding affinity predicted from footprinting studies using 
poly(N-methylpyrro1e)-containing peptides equipped with a 
DNA cleaving agent (Youngquist & Dervan, 1985). These 
studies indicated that the preference of hydrogen bonds be- 
tween the three amide groups of netropsin and adjacent bases 
on opposite helix strands decreases in the order AT >> AA > 
TT for sites having only adenine and thymine. As is evident 
from Table I, sites AATT and TTAA possess netropsin binding 
constants which differ by 2 orders of magnitude. Since the 
bridged-base possibilities within the sites are similar (AT, TT, 
and TA for AATT; TA, AA, and AT for TTAA), it appears 
that factors other than the number and type of bridged base 
pairs are important in determining the affinity of the antiviral 
agent. As stated earlier, structural changes in DNA, due to 
adenine-adenine clashes within the minor groove, are the most 
likely cause for the observed differences in the affinities as- 
sociated with the AT tetramers. 
Scope, Limitations, and Errors Associated with Quantita- 
tive Footprinting Analysis. A number of sources of error in 
the quantitative footprinting experiment need to be considered. 
Although the number of pieces of data is, in general, much 
greater than the number of parameters to be calculated, there 
are some cases for which constants cannot be determined 
accurately. For instance, KlS6  is derived from intensity data 
associated with a single band, located at position 154 on the 
autoradiogram, Figure 2. Because only a single band is in- 
volved and the site is in a poorly resolved region of the auto- 
radiogram, the determined value of K is subject to considerable 
error. 
The fragment concentration was not specifically determined 
in the analysis. Its concentration was estimated from an initial 
determination of the plasmid concentration (using optical 
methods) and an assumed total recovery of the fragment in 
the labeling and isolation procedures. To determine the sen- 
sitivity of the determined value of K for the various sites, trial 
calculations using altered values of the fragment base pair 
concentration for the experiment involving no carrier DNA 
were carried out. The value assumed for all experiments, 10" 
M in base pairs or 7.2 X M in fragment concentration, 
was first increased by half and then decreased by one-third. 
The results, given in Table 11, show that there are only very 
slight changes in equilibrium constants when the fragment 
concentration is altered. The change can only be small as long 
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as the maximum concentration of bound drug (fragment 
concentration times number of sites per fragment which can 
be occupied simultaneously) is not comparable to the total drug 
concentration. This is realized for our experiments. 
One should also recall that, in the studies involving calf 
thymus DNA as carrier, the fragment concentration does not 
directly enter into the determination of the equilibrium con- 
stants associated with the fragment. In this case, the carrier, 
which is in a greater than 100-fold excess over the fragment, 
controls the concentration of free drug. In the studies involving 
calf thymus DNA, the concentration of strong netropsin sites 
on the carrier was assumed to be M, and the effective 
binding constant K, to a site on the carrier was taken as an 
additional parameter to be found in the minimization proce- 
dure. A value of K, for the carrier of 1 X lo6 M-' was found 
to give the best tit between theory and experiment for the data. 
In fact, only the product of K, and the number of binding sites 
on the carrier is significant. 
For the experiments involving poly(dGdC) as carrier, it was 
assumed that no drug binding to the carrier takes place. 
However, recent studies have shown that the binding constant 
of netropsin toward poly(dGdC) is -5 X los M-' (Marky & 
Breslauer, 1987). This value of K,, along with the fact that 
the carrier concentration is about 2 orders of magnitude greater 
than that of the fragment, may mean that binding to the 
carrier cannot be ignored in the analysis. This would mean 
that the free drug concentrations were actually lower than what 
we calculated by assuming no binding to the carrier. The use 
of free drug concentrations higher than the actual ones would 
give low values for all of the binding constants. As Table I 
indicates, the constants found from poly(dGdC) experiments 
are in fact much lower than those from the other experiments. 
Assuming an effective binding constant of lo5 M-' for drug 
on poly(dGdC) and using the known concentration of sites on 
this carrier (35 pM), we used the experimental data in a fitting 
procedure to determine the binding constants for the fragment. 
We indeed found binding constants of the same size as those 
found from the no carrier and calf thymus DNA carrier ex- 
periments. We also attempted to use the effective binding 
constant to poly(dGdC) as a variational parameter and find 
the value which gave the best agreement between theoretical 
and experimental data by minimizing the deviation. The 
search was not successful, multiple minima being found. This 
is because, for a wide range of values for the effective binding 
constant, there exists a set of Ki which can produce agreement 
of theoretical binding curves with our experimental data, within 
the errors of the latter. 
In the case of the experiments using calf thymus DNA as 
carrier, the minimization algorithm converged. We did not 
find solutions (sets of equilibrium binding constants Ki which 
lead to minimum deviation between theoretical and experi- 
mental intensities) for which the Ki were very different from 
values reported. Further, as shown in Table I, the Ki values 
are in good agreement with those obtained from the no carrier 
experiment. Apparently, the range of acceptable values for 
K,, the effective binding constant to the carrier, is not so wide 
in this case, and/or there is a small correlation between K,  
and K,, the site binding equilibrium constants to the fragment, 
in this range of K,. The latter would occur, for example, if 
K,  were small, so as to make Do similar to D, for most of the 
drug concentrations investigated. 
The possibility that drug binding to the fragment occurs in 
a cooperative manner was not addressed in the study. Unlike 
numerous intercalating agents, netropsin binds without greatly 
distorting the DNA helix (Kopka et al., 1985). This obser- 
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vation and the fact that the initial loading events on the 
139-mer are generally well separated from each other strongly 
suggest that binding, at least for the strong sites, occurs in an 
independent noncooperative fashion, and thus the analysis 
presented here is valid. 
There may also be an error connected with the correction 
for enhancement (Ward et al., 1987, 1988) made according 
to eq 3 in the determination of binding constants. While the 
enhancement was generally small and relatively uniform over 
long segments of DNA remote from drug binding, it appeared 
to be 2-3 times greater at sites adjacent to a netropsin binding 
site on DNA. The reason for this is unclear, but since net- 
ropsin does not greatly distort DNA, it does not appear to be 
structural in origin. The presence of this effect would also 
assign netropsin sites 56 and 46 a larger enhancement factor 
than, for example, that of site 89 and lead to an increase in 
the calculated binding constants of the weak sites at positions 
46 and 56. However, the increase would be modest 
so the large differences found between the values of K for these 
sites and those of the strong sites appear to be due to se- 
quence-dependent DNA structural effects rather than to ar- 
tifacts associated with the enhancement. 
In the analysis, seven nucleotide positions were assumed to 
be equally affected by the binding of a single netropsin 
molecule to DNA, except for the isolated site at 89-92, because 
the footprinting plots for the region 85-92 show that site 85 
exhibits partial protection by the drug which is bound at 89-92. 
Thus, in this case the geometry of the enzyme may block 
cleavage four base pairs to the 3r side of a drug binding site 
rather than three, yielding a protection region eight nucleotides 
long rather than seven. If we assume the protection region 
is eight nucleotides long everywhere, we find significantly 
poorer agreement between the experimental and calculated 
intensities (sum of squared deviations). This is because, if the 
protection region were eight nucleotides in length, the inten- 
sities for site 55 would decrease with drug concentration in 
exactly the same way as for sites 57, 58, and 59, and this is 
clearly not borne out by the data (see supplementary material). 
Thus one must assume seven sites are protected here. These 
observations suggest that the protection region may be con- 
trolled not only by the size of the drug and the geometry of 
the cleavage agent but, to a certain extent, also by the sequence 
at which binding is taking place. 
The data for site 85 suggest that the protection is less than 
that observed at sites 87, 90, and 92. This may be taken into 
account by replacing eq 2 by 
(rate), = k,[DNase I]p, + krri[DNase IIi(l - p i )  
where k’: is a cleavage rate constant for a blocked site, as was 
done by Brenowitz et al. (1986a). However, this would sig- 
nificantly increase the number of variable parameters leading 
to a decrease in the significance of the values obtained. 
The method described is independent of the magnitudes of 
the association/dissociation rates of the ligand and the cleavage 
rate of the probe (Goodisman & Dabrowiak, 1986). If the 
ligand-DNA interaction is at equilibrium before the addition 
of the probe and remains so during the time of the digest, the 
concentrations of oligonucleotide products, after correction for 
any alterations in the probe-DNA equilibrium, reflect the 
fraction of a particular site which is occupied by ligand. Since 
a DNA cleaving probe is being used to report the amount of 
a particular site which is occupied by ligand, the possibility 
exists that the probe itself shifts the ligand-DNA equilibrium 
and that a competitive equilibrium is being measured. At least 
for DNase I and the strong netropsin binding sites on the 
fragment this does not appear to be the case. Although the 
enzyme/DNA ratios were different in the calf thymus DNA 
and no carrier experiments, both experiments returned the 
same binding constants, indicating that the enzyme is not 
disturbing the drug-DNA equilibrium. 
CONCLUSIONS 
In this paper we have presented the theory for quantitative 
analysis of a drug-DNA footprinting experiment. The ap- 
proach incorporates enhancements due to redistribution of 
DNase I on DNA, as well as exclusion associated with over- 
lapping binding sites on DNA. By use of the theory with the 
autoradiographic spot intensities obtained from three sets of 
footprinting experiments involving a 139 base pair restriction 
fragment of pBR-322 DNA, binding constants for the antiviral 
agent netropsin as a function of sequence were determined. 
The analysis revealed that the presence of the dinucleotide 
sequences TA within sites of the type (A-T), greatly dis- 
courages netropsin binding to DNA. This effect very likely 
has its origins in a strong clash between adenines on opposite 
polynucleotide strands, which produce an altered DNA 
structure not optimal for netropsin binding. The scope, lim- 
itations, and errors associated with the new method were also 
presented and discussed. 
SUPPLEMENTARY MATERIAL AVAILABLE 
Tables 1-111 giving the experimentally determined and 
calculated concentration (areas) ai values for the various ex- 
periments (3 pages). Ordering information is given on any 
current masthead page. 
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ABSTRACT: The properties of the high-affinity single-stranded DNA (ssDNA) binding state of Escherichia 
coli recA protein have been studied. We find that all of the nucleoside triphosphates that are  hydrolyzed 
by recA protein induce a high-affinity ssDNA binding state. The effect of ATP binding to recA protein 
was partially separated from the ATP hydrolytic event by substituting calcium chloride for magnesium chloride 
in the binding buffer. Under these conditions, the rate of ATP hydrolysis is greatly inhibited. ATP increases 
the affinity of recA protein for ssDNA in a concentration-dependent manner in the presence of both calcium 
and magnesium chloride with apparent Kd values of 375 and 500 pM ATP, respectively. Under nonhydrolytic 
conditions, the molar ratio of ATP to ADP has an effect on the recA protein ssDNA binding affinity. Over 
an ATP/ADP molar ratio of 2-3, the affinity of recA protein for ssDNA shifts cooperatively from a low- 
to a high-affinity state. 
%e recA protein has been shown to bind to single-stranded 
DNA (ssDNA)I (McEntee et al., 1981; Silver & Fersht, 1982; 
Menetski & Kowalczykowski, 1985). The affinity of recA 
protein for ssDNA is influenced by the presence of ATP, ADP, 
and NaCl (Menetski & Kowalczykowski, 1985). Increasing 
the concentration of ADP and NaCl decreases the affinity, 
while the presence of ATP increases the affinity of recA 
protein for ssDNA. Weinstock et al. (1981) have shown that 
recA protein can hydrolyze other nucleoside triphosphates in 
addition to ATP. In this paper, we have extended our previous 
analysis of the modulation of recA protein ssDNA binding 
affinity by nucleotide cofactors to include those nucleotides 
having significant concentrations in vivo. The data show that 
all nucleotides which are hydrolyzed by recA protein induce 
a high ssDNA binding affinity state similar to that induced 
by ATP. 
The ATP-induced high-affinity state was first observed 
(Silver & Fersht, 1982) and characterized (Menetski & 
Kowalczykowski, 1985) under conditions which support the 
ATPase activity of recA protein. Therefore, the data reflect 
only the steady-state effect of ATP on recA protein ssDNA 
binding affinity. Under these conditions, the individual effects 
of binding and hydrolysis of ATP cannot be clearly separated. 
Ideally, the two events could be separated under conditions 
that prevent hydrolysis but not nucleotide binding. Weinstock 
et al. (1981) have reported that in the presence of CaCl,, the 
rate of ATP hydrolysis is less than 10% of that observed in 
MgC1,. We have found that ATP is indeed bound to recA 
protein in the presence of CaCl, and that ATP induces a high 
ssDNA binding affinity state similar to the one observed in 
MgC1,. This result shows that only ATP binding, and not 
hydrolysis, is required to induce the high-affinity state. Under 
conditions of reduced hydrolysis, the affinity of all recA protein 
molecules for ssDNA is sensitive to the ATP/ADP molar ratio 
in the buffer. As the ATP/ADP molar ratio decreases, the 
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I Abbreviations: etheno M13 DNA, modified ssDNA containing 
1 ,N6-ethenoadenosine and 3,N4-ethenocytosine; ssDNA, single-stranded 
DNA; dsDNA, double-stranded DNA; ATPyS, adenosine 5’-0-(3-thio- 
triphosphate); poly(dA), poly(deoxyadeny1ic acid); RFI, relative 
fluorescence increase; Tris-HCI, tris(hydroxymethy1)aminomethane hy- 
drochloride; SSB protein, E .  coli single-stranded DNA binding protein. 
0 1988 American Chemical Society 
